A standardised record for every compound

A long-acting GLP-1 receptor agonist approved for type 2 diabetes and, at higher doses, chronic weight management. One of the most extensively studied peptide medicines in modern endocrinology.

A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with an expanding trial programme across cardiometabolic and sleep-related indications.

An investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 data have been reported; it is not an approved medicine anywhere.

A synthetic pentadecapeptide widely marketed online and frequently discussed in injury-recovery contexts. Human evidence is very limited, and it is not an approved medicine.

A synthetic fragment related to thymosin beta-4, marketed for tissue repair claims. Human clinical evidence is minimal, and it is prohibited in sport.

A growth-hormone-releasing hormone analogue approved for a narrow indication: reduction of excess abdominal fat in people with HIV-associated lipodystrophy.

A selective growth hormone secretagogue studied in early clinical work and later discontinued. It is not an approved medicine and is widely sold in unapproved channels.

A long-acting GHRH analogue investigated in early trials and never approved. Commonly marketed in unapproved channels alongside other secretagogues.

A copper-binding tripeptide used in cosmetic skincare formulations. Regulated as a cosmetic ingredient rather than a medicine; evidence is mostly small studies and laboratory work.